Wugen
Engineering the Next Generation of Off-the-Shelf Cell Therapies
St. Louis, United States
51 employees
Series C
Total: $323.00M
Biotechnology, Health and Wellness
General Information
Get notified when Wugen moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Discover More
United States Market
Biotechnology
About Wugen
Taxonomy: cell therapy, off-the-shelf, NK cells, CAR-T cells, cancer, Moneta platform, genomic engineering, immuno-oncology, AML, solid tumors, clinical-stage, St. Louis, San Diego, memory NK cells
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | •••••• | 8 |
|
01 Aug 2025 |
| Series B | •••••• | 11 |
|
01 Jul 2021 |
| Series A | •••••• | - | 01 Apr 2020 | |
| Seed | •••••• | - | 01 Jan 2019 | |
| Spinout | •••••• | 1 | •••• •••• | 01 Jan 2018 |
Wugen Alternatives & Competitors
Collaborates across a diversity of disciplines, which is critical to developing next-generation ther...
Pioneering thymus-empowered T-cell platform to fight cancer and infection
vs
TC BioPharm
FAQ About Wugen
Don't just browse. Track.
Signal Tracker monitors Wugen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
